RAS Mutations Enhance Chemotherapy in AML

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

NSCLC Experts Ponder Best First-Line Treatment Options

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

University of Chicago Thought Process on First-line Treatment in EGFR NSCLC

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Referring to the NCCN guidelines for the treatment of EGFR-mutated NSCLC will help clinicians determine which treatments are best recommended.

Related Content

Tim Cortese

January 18th 2025

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

NSCLC Experts Ponder Best First-Line Treatment Options

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

University of Chicago Thought Process on First-line Treatment in EGFR NSCLC

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.